Skip to main content
padlock icon - secure page this page is secure

Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System

Buy Article:

$52.00 + tax (Refund Policy)

Abstract

Little is known about tumor-related prognostic factors, in particular specific chromosomal abnormalities, in young patients with multiple myeloma (MM). We therefore investigated the chromosomal pattern by interphase fluorescence in situ hybridization (chromosomes 13q14, 14q32-translocations, chromosomes associated with hyperdiploidy) in 38 young patients with MM (age <45 yr) and compared the results with those observed in 69 patients with intermediate age (45–70 yr) and 64 elderly patients (age >70 yr). All chromosomal patterns were not significantly different between the three age cohorts. Similarly, standard MM parameters were equally distributed between these MM patient populations. However, survival by the International Staging System (ISS) for MM revealed marked differences between stage I/II (median survival not yet reached) and stage III (23.4 months; P < 0.0003) among young MM patients. A significant survival difference between ISS-stage I/II and ISS-stage III patients was also noted in the intermediate age group (median 65.4 months vs. 24.6 months; P = 0.0009). However, this difference disappeared among elderly MM patients (39.6 months in ISS-stage I/II vs. 32 months in ISS-stage III patients; P = 0.94), but it was unrelated to the cytogenetic pattern. Our results indicate that MM in young patients does not represent a distinct biologic entity, and that short survival of younger MM patients at ISS-stage III is independent of the molecular cytogenetic pattern.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: International Staging System stage; age; molecular cytogenetics; multiple myeloma; prognosis

Document Type: Research Article

Affiliations: 1: Department of Internal Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna 2: Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna 3: Department of Internal Medicine I, Bone Marrow Transplant Unit, Medical University of Vienna, Vienna 4: Department of Medicine I, Cente of Oncology and Hematology, Wilhelminenspital, Vienna 5: Department of Internal Medicine III and Ludwig-Boltzmann-Institute for Leukemia Research and Hematology, Hanuschspital, Vienna, Austria

Publication date: March 1, 2007

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more